The market size of the Global Plasma Fractionation Market in the year 2021 is valued at 21.42 billion and is predicted to reach 40.45 billion by the year 2030 at an 6.40% CAGR during the forecast period.
Curious about this latest version of report? Obtain Report [email protected] https://www.insightaceanalytic.com/report/global-plasma-fractionation-market/1262
Fractionation is a technique of separating a specific amount of a mixture. Plasma is the fluid component of blood that is isolated to produce albumin and immunoglobulins, among other plasma derivatives. The rise in the global geriatric population, which is prone to a variety of uncommon disorders that necessitate the usage of plasma derivatives, is a primary reason driving the plasma fractionation market forward.
Also, the increased use of immunoglobulins and alpha-1-antitrypsin in medical fields worldwide is propelling the plasma fractionation market forward. Furthermore, increasing plasma collecting facilities worldwide is a crucial driver driving the market forward. Similarly, positive government support for raising knowledge about the usage of plasma-derived goods boosts the industry’s growth. Plasma fractionation products have therapeutic properties and are used in the treatment of a variety of illnesses. Besides, strict government regulations and a reduction in plasma supply due to poor donor turnout are expected to limit the market’s growth to a certain amount throughout the forecast period. The rising prevalence of AATD and emphysema and advances in diagnostic procedures like C.T. scanning are expected to increase the number of people receiving treatment for these disorders. As a result, demand for protease inhibitors such as alpha-1-antitrypsin will increase, contributing to the overall growth of the plasma fractionation market. However, the high cost and limited reimbursement for plasma products and the growing usage of recombinant alternatives are restricting the market’s growth.
List of Prominent Players in the Plasma Fractionation Market:
- S.L. Limited
- Grifols, S.A.
- Octa Pharma AG
- Kedron S.P.A.
- Shire Plc (Subsidiary of Takeda Pharmaceutical Company Limited)
- Biotest AG
- China Biologic Products Holdings, Inc.
- Bio Products Laboratory (BPL) Ltd
- Japan Blood Products Organization
- Shanghai RAAS Blood Products Co., Ltd.
For More Information @ https://www.insightaceanalytic.com/report/global-plasma-fractionation-market/1262
One of the key factors driving the plasma fractionation market ahead is the growing worldwide elderly population, which is prone to a range of rare ailments that demand the use of plasma derivatives. The rising use of immunoglobulins and alpha-1-antitrypsin in medical fields worldwide is also moving the plasma fractionation industry ahead. Furthermore, the expansion of plasma collection facilities around the world is a vital driver of the market. Moreover, the industry’s expansion is aided by positive government assistance in spreading awareness about the use of plasma-derived products. Plasma fractionation products are used to treat a range of ailments and have therapeutic characteristics.
However, the market’s growth is being hampered by the high cost and limited reimbursement for plasma products and the expanding use of recombinant alternatives. Furthermore, strict government regulations and a reduction in plasma supply due to the low donor turnout are expected to limit market growth to a certain degree throughout the forecast period. The COVID-19 pandemic had a negative impact on the number of blood money donated around the world. Due to the worldwide lockdowns, the number of blood donors at plasma donation facilities and blood donation centres has decreased dramatically.
The Asia Pacific Plasma Fractionation Markets are expected to register significant market share in terms of revenue and are projected to grow at a high CAGR soon. Rising consumption of plasma-derived products, strategic developments made by companies in this region, presence of leading players, contract fractionation agreements between countries, and programs to increase plasma use and fractionation are the factors driving the growth of the Asia Pacific plasma fractionation market. The increasing use of immunoglobulins in neurological and autoimmune illnesses and the increasing usage of preventative treatments among diagnosed patients are responsible for North America’s high proportion of the global market. This market’s growth is further aided by a large number of registered hemophilic patients.
- In January 2022, Permira, a global investment firm, announced that it would be acquiring Kedron and merging the company with BPL. The merger will establish a worldwide player in the field of medications generated from human blood plasma, which are used to treat patients with uncommon and life-threatening diseases.
- In August 2021, C.S.L. (Australia) Received F.D.A. approval for the new BERINERT [C1 Esterase inhibitor, Human (Intravenous)] Administration Kit for improved patient convenience.
Segmentation of Plasma Fractionation Market –
- Coagulation Factors
- Protease Inhibitors
- Other Products
- Critical Care
- Other Applications
- Hospitals& Clinics
- Clinical Research Laboratories
- Academic Institutes”
- The US
- The UK
- Rest of Europe
- South Korea
- South East Asia
- Rest of Asia Pacific
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Request for ToC/Proposal: https://www.insightaceanalytic.com/request-sample/1262